Category icon
Dyslipidaemia in the Real World

Ricardo Lopez Santi, Felipe Martínez, Adrian Baranchuk, et al

Category icon
Coronary CT Angiography-derived FFR

Lavanya Cherukuri, Divya Birudaraju, Matthew J Budoff,

Category icon
Inflammation in Coronary Epicardial and Microvascular Dysfunction

Shigeo Godo, Jun Takahashi, Satoshi Yasuda, et al

Category icon
Editorial: The EXCEL Trial

Pablo Avanzas, Juan Carlos Kaski,

Category icon
Bridging the Gap in a Rare Cause of Angina

Sumanth Khadke, Jovana Vidovic, Vinod Patel,

Category icon
Pharmacotherapy in Stable CAD: The ISCHEMIA Trial

Jonathan Yap, Derek P Chew, Gregg W Stone, et al

Category icon
The Core Message of ISCHEMIA

Kreton Mavromatis, William E Boden,

Category icon
ISCHEMIA: A Clinician’s Perspective

Islam Y Elgendy, Carl J Pepine,

About

Coronary artery disease (CAD) is one of the most common causes of death worldwide. It is responsible for one-third of deaths in people over 35 years old, with the percentage reaching close to 50% (according to some estimates) in western countries.

The existing treatment is medical, surgical or a combination of both depending on the extent, severity and clinical presentation of CAD & .There has been significant progress made in developing novel strategies for patients suffering from CAD and its associated complications. These strategies have ranged from drugs to robotic surgery to nanotechnology.

Related Articles

Articles

Article icon
Editorial: The EXCEL Trial

Pablo Avanzas, Juan Carlos Kaski,

Published:

Citation: European Cardiology Review 2021;16:e09.

Bridging the Gap in a Rare Cause of Angina

Sumanth Khadke, Jovana Vidovic, Vinod Patel,

Published:

Citation: European Cardiology Review 2021;16:e05.

Pharmacotherapy in Stable CAD: The ISCHEMIA Trial

Jonathan Yap, Derek P Chew, Gregg W Stone,

Published:

Citation: European Cardiology Review 2021;16:e04.

Current Evidence and Future Directions of PCSK9 Inhibition

Jiaqian Xu, Michael D Shapiro,

Published:

Citation: US Cardiology Review 2021;15:e01.